
HTGF et al. back InnoCyte
High-Tech Gründerfonds (HTGF), the Mittelständische Beteiligungsgesellschaft (MBG) and Fraunhofer Venture have invested a six-figure sum in German medical device company InnoCyte.
The financing will push growth and further advance the company's technology, Split.It, before it enters the market in the summer of 2013.
Company
InnoCyte has developed a laboratory desktop device called Split.It that simplifies the production of biological cells, focusing on the central routine process of "passage".
The company is a spin-off from the Fraunhofer Institute for Production Technology and Automation IPA and was already supported financially by Fraunhofer at its foundation in the summer of 2011.
Over the next few years Split.It plans to add various further devices focused on automated cell cultures, resulting in a complete family of products.
People
Fraunhofer's Matthias Keckl, HTGF investment manager Matthias Dill and MBG investment manager Florentin Walker worked on the deal.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater